To Top


Purple Biotech Ltd. is a clinical-stage company focusing on the development of first-in-class, effective therapies that harness the power of the tumor microenvironment (TME) to overcome drug resistance and improve treatment outcomes for cancer patients.

Our oncology pipeline includes NT219, CM24 and and a Tribody platform

NT219 is a small molecule targeting the novel cancer drug resistance pathways IRS1/2 and STAT3. We are currently planning the phase 2 study of NT219 at its RP2D level in combination with cetuximab for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck in the first half of 2024.

CM24 is a monoclonal antibody blocking CEACAM1, a novel immune checkpoint that supports tumor immune evasion and survival through multiple pathways. Purple Biotech has entered into a clinical collaboration agreement with Bristol Myers Squibb for the phase 1/2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab (Opdivo®) in addition to chemotherapy in patients with pancreatic cancer.

We are developing a Tribody Platform which includes a conditionally-activated tri-specific antibodies that engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The cleavable capping technology confines the compound’s therapeutic activity to the local tumor microenvironment, and thereby potentially increases the anticipated therapeutic window in patients. The third arm of the antibody specifically targets the Tumor Associated Antigen (TAA). The technology presents a novel mechanism of action by unleashing both innate and adaptive immune systems to mount an optimal anti-tumor immune response.. IM1240 is our platform’s lead tribody in development that targets 5T4 expressed in a variety of solid tumors and is correlated with advanced disease, increased invasiveness and poor clinical outcomes. Currently, we are conducting the preclinical studies required for IND-filing.

Purple History

Our Mission


Executive Team


Chief Executive Officer


Chief Financial Officer


Head of Clinical and Regulatory Affairs


Vice President Research & Development


Vice President Operations

Board of Directors

Eric Rowinsky, M.D. has served as the Chairman of Purple Biotech’s Board since October 2019. Dr. Eric Rowinsky’s principal expertise is in the development and registration of novel therapeutics to treat cancer and related disorders. Dr. Rowinsky currently serves as consulting Chief Medical Officer and/or advisor for drug development and registrational strategies to several biopharma companies worldwide. Dr. Rowinsky has served as the Chief Medical Officer of Hummingbird Biotherapeutics, a life-science company from 2016 to 2023. From 2015 to 2021, Dr. Rowinsky served as Executive Chairman of the Board of Directors and President of Inspira, Inc. (formerly Rgenix, Inc) and is currently serving as its President, Chairman of the Scientific Advisory Board, and Director. Dr. Rowinsky also served as the Chief Scientific Officer of Clearpath Development Inc., from 2015-2021, and has served as a consulting Chief Medical Officer of Oncotartis, Inc. since 2018 and as an advisor to Everest Medicines, Inc. since 2017. Dr. Rowinsky served as Executive Vice President, Chief Medical Officer and Head of Research and Development of Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, from November 2011 until October 2015. Prior to joining Stemline, Dr. Rowinsky was co-founder and Chief Executive Officer of Primrose Therapeutics, Inc., a start-up biotechnology company, from June 2010 until its acquisition in September 2011. Dr. Rowinsky also served as a drug development and regulatory strategy consultant to the ImClone-Lilly Oncology Business Unit and several other biopharmaceutical and life sciences companies from 2010 to 2011. From 2005 to 2009, Dr. Rowinsky was Executive Vice President and Chief Medical Officer of ImClone Systems Inc., where he led the FDA approval of Erbitux for head and neck and colorectal cancers and advanced eight other monoclonal antibodies through clinical development. From 1996 to 2004, Dr. Rowinsky held several positions at the Cancer Therapy and Research Center, including Director of the Institute of Drug Development, or IDD, and the SBC Endowed Chair for Early Drug Development at the IDD. From 1996 to 2006, Dr. Rowinsky was a Clinical Professor of Medicine at the University of Texas Health Science Center at San Antonio. From 1988 to 1996, Dr. Rowinsky was an Associate Professor of Oncology at The Johns Hopkins University School of Medicine. Dr. Rowinsky was a longstanding National Cancer Institute principal and co-principal investigator from 1990 to 2004, and was integrally involved in pivotal clinical and preclinical investigations that led to the development of numerous cancer therapeutics, including paclitaxel, docetaxel, topotecan, irinotecan, erlotinib, gefitinib, ramucirumab, tagraxofusp and temsirolimus among others. Dr. Rowinsky was also an Adjunct Professor of Medicine at New York University School of Medicine (2008-2018). Dr. Rowinsky presently serves on the boards of directors of the public companies Biogen Idec, Inc., Fortress Biosciences, Inc., and Verastem Inc. Dr. Rowinsky formerly served on the boards of directors of the public companies Navidea Biopharmaceuticals Inc. (2010-2018), BIND Therapeutics (2014-2016), and Biophytis S.A. (2018-2019), as well as at a number of privately held companies. Dr. Rowinsky received a B.A. degree from New York University (1977) and an M.D. degree from Vanderbilt University School of Medicine (1981). Dr. Rowinsky completed his residency in internal medicine at the University of California, San Diego (1984) and completed his fellowship in medical oncology at The Johns Hopkins Oncology Center (1987).
Isaac Israel has served as a member of our Board of Director since October 2012. Currently, Mr. Israel provides advisory services to the Company since July 2022. Prior to that, from October 2012 until July 2022, Mr. Israel served as the Company’s Chief Executive Officer. Mr. Israel was the founding Chief Executive Oficer of BeeContact Ltd. (formerly TASE:BCNT), from 2001 until 2007. Since 2008, Mr. Israel has served as founding Chief Executive Officer of Uneri Capital Ltd., a consulting firm in the capital markets field, owned by Mr. Israel, which specializes in the healthcare sector. Mr. Israel served as a member of the board of directors and as chairman of the board of various private and public healthcare corporations.
Simcha Rock has served a member of our Board of Directors since July 2013. Mr. Rock served as a strategic consultant to Purple Biotech from January 2019 until December 2019. Mr. Rock served as our Chief Financial Officer from July 2013 until December 31, 2018. Prior to joining us, Mr. Rock was a private equity manager at Edmond de Rothschild Private Equity Management, a firm specializing in the management of venture capital and other private equity investments funds, from February 2000 until January 2011, with responsibility for all financial, legal and administrative matters for several investment funds. Prior to 2000, Mr. Rock held financial management positions at Intel Electronics Ltd., The Jerusalem College of Technology, and JC Technologies Ltd. Mr. Rock holds a B.A. degree from Yeshiva University and an MBA degree from Cleveland State University, and is a certified public account.
Ido Agmon, MBA, has served as a member of Purple Biotech's Board since June 2016. Since 2012, Mr. Agmon has been acting as an independent consultant and investment manager, providing start-ups, investment funds and technology-based ventures with advice in strategic & financial planning, fund-raising and related business development activities. From 2014 until the end of 2016, Mr. Agmon was a manager of Aviv New-Tech (formerly Aviv Bio-Invest), a private investment fund which manages a portfolio of public Israeli & global biomed and technology companies, of which he was a co-founder, and where he was responsible for analysis and evaluation of investments in Israeli and global biomed companies. From 2009 until 2011, Mr. Agmon served as the CEO of Meytav Technology Incubator, an Israeli-based accelerator for biotech, pharma & medtech ventures with over 20 portfolio companies. Mr. Agmon has served as a board member at a number of biomed ventures. From 2007 until 2009, he worked as the Director of Business Development at ATI incubator, a technology incubator specializing in biomed and cleantech projects, responsible for deal-flow and project evaluation. Mr. Agmon holds a Bachelor’s Degree in Business Administration & Life Sciences from Tel Aviv University, Tel Aviv, Israel, and an MBA from The Hebrew University, Jerusalem, Israel.
Ori Hershkovitz has served as a member of Purple Biotech’s Board since December 2021. Mr. Hershkovitz has held various positions in life sciences investment funds over many years. Mr. Hershkovitz serves as a financial advisor to financial institutions in cooperation with Cantor Fitzgerald L.P. since 2023. Mr. Hershkovitz has served as a board member and a senior advisor to private and public biotechnology and healthcare companies since 2010. Mr. Hershkovitz served currently serves on the Board of Directors of Matricelf Ltd. (TASE: MTLF) from 2021 to 2023, and served from 2013 to 2016 as a member of the Board of Directors of MicroMedic Ltd. (TASE:MCTC) and Medigus Ltd. (Nasdaq: MDGS). From 2015 to 2019, Mr. Hershkovitz served as a Managing Partner and chief investment officer of Nexthera Fund, a healthcare hedge fund based in New York, managing over $400 million in assets. From 2006 to 2014, Mr. Hershkovitz was the Managing Partner and Head of Research at Sphera Fund in Tel Aviv, managing over $700 million in assets. From 2001 to 2006, Mr. Hershkovitz served as Senior Pharmaceutical Equity Analyst at Leader & Co. Investment House Ltd. in Tel Aviv, and from 1999 to 2001, he was a Pharmaceutical Equity Analyst at Ilanot Batucha Investment House Ltd. Mr. Hershkovitz holds a B.A degree in Business Administration and Finance from Tel Aviv University and is a licensed investment advisor.
Robert Gagnon has served as a member of Purple Biotech’s Board since March 2021. Mr. Gagnon currently serves as Chief Financial Officer of Remix Therapeutics. Prior to that, Mr. Gagnon was an Chief Financial Officer / Operating Partner of Gurnet Point Capital, a healthcare venture capital and private equity fund. Prior to joining Gurnet Point Capital in 2022, Mr. Gagnon was Chief Financial Officer / Chief Business Officer of Verastem Oncology. Before joining Verastem in 2018, Mr. Gagnon served as the Chief Financial Officer at Harvard Bioscience, Inc. Prior to that, Mr. Gagnon served as Executive Vice President, Chief Financial Officer and Treasurer at Clean Harbors, Inc., as well as Chief Accounting Officer and Controller at Biogen Idec, Inc. Earlier in his career, Mr. Gagnon worked in a variety of senior positions at Deloitte & Touche, LLP and PricewaterhouseCoopers, LLP. Mr. Gagnon holds an M.B.A. degree from the MIT Sloan School of Management and a B.A. degree in accounting from Bentley College. Mr. Gagnon is a board member of Verastem Oncology, Inc. and Bone Biologics, Inc.
Suzana Nahum-Zilberberg has served as a member of our Board of Directors since May 2021. Ms. Nahum-Zilberberg currently serves as Vice Chairman of the Board of BioLight Life Science, which is traded on the Tel Aviv Stock Exchange, and from 2011 to 2020 served as the CEO of BioLight. Ms. Nahum-Zilberberg also serves as a director at Human Xtention Ltd., Matricelf Ltd and Nextferm Technologies Ltd., all of which are traded on the Tel Aviv Stock Exchange, and a number of private companies. Prior to joining BioLight, Ms. Nahum-Zilberberg held a number of leadership positions at Teva Pharmaceuticals Industries, including Vice President of Asia and Pacific and Director in the office of the President and CEO. Ms. Nahum-Zilberberg holds a B.A. degree in accounting and economics and a M.B.A. degree, both from Tel Aviv University, a Certified Director degree from Tel Aviv University, and studied at the INSEAD Asian International Executive Program. She is a certified public accountant.
Dr. Yael Margolin has served as a member of our Board of Directors since December 2023. Since 2019, Dr. Margolin has served as a board member to several public and private companies in the healthtech industry, including: Point Biopharma Global (NASDAQ: PNT), Scinai Immunotherapeutics (NASDAQ: SCNI), Quris AI, MakeSense, Neovac, Welltech Ventures, Ramot at Tel Aviv University and TAU Ventures by Tel Aviv University. From 2005 to 2019, she served as President, Chief Executive Officer and director of Gamida Cell Ltd. (NASDAQ: GMDA), a clinical stage biopharmaceutical company, leading the company from preclinical development through phase 3 international registration studies. Prior to that, she was Vice President of Denali Ventures LLC, a venture capital firm focused on healthcare, and a program manager at Teva Pharmaceuticals. Dr. Margolin is a founder of mentoring@8400, a boutique voluntary mentoring program for young CEOs in Israel. Dr. Margolin holds a BSc in biology and a MSc Cum Laude both from Tel Aviv University in Israel, a Ph.D. from the Weitzman Institute of Science in Israel and was a post-doctoral associate at the Yale University School of Medicine.

Scientific Advisory Board

Eyal Gottlieb, PhD, is a Professor at the Department of Cancer Biology and Vice President for Research at The University of Texas M.D. Anderson Cancer Center (MD Anderson). Before joining MD Anderson in January 2023, he was Director of the Rappaport Institute for Biomedical Research, Vice Dean of Research and the Laura and Isaac Perlmutter Chair of Cancer Research at the Ruth and Bruce Rappaport Faculty of Medicine at Technion - Israel Institute of Technology. Previously, based on his independent research he became a Group Leader at the Cancer Research UK, Beatson Institute, where he established the Cancer Metabolism Research Unit and was appointed Professor of Molecular Cell Biology at the University of Glasgow. His research, which focuses on the metabolic vulnerabilities of cancer cells created by genetic or environmental constraints, has yielded several key discoveries on the tumor microenvironment that are useful to research and industry. He is a Senior Editor at Cancer Research, a member of multiple editorial boards and has co-founded two biotech companies.
Steven Maron, MD, MSc, is a medical oncologist at Memorial Sloan Kettering Cancer Center (MSK) who specializes in treating gastrointestinal malignancies with a focus on esophageal and stomach cancers. His research focuses on applying informatics to identify novel therapeutic targets and to improve patient selection for targeting and immunotherapies. He has a particular interest in elucidating tumor heterogeneity and developing clinical trials aimed at overcoming this barrier. His research has been supported by grants from the National Cancer Institute, Conquer Cancer Foundation, American Association of Cancer Research, Society of MSK, Cycle for Survival, Ullman Fund for Cancer Immunology, and Castle Foundation.
Sunil Sharma, MD, MBA, is Physician in Chief, Deputy Director of Clinical Sciences and Professor and Division Director of Applied Cancer Research and Drug Discovery at Translational Genomics (TGen), and also Professor of Medicine at City of Hope. His laboratory focuses on drug discovery and translational research for novel cancer therapies, including epigenetics and immune pathways. Under his direction, his lab has discovered multiple compounds that are in pre-clinical and clinical development to treat various solid tumors. As a practicing oncologist, he focuses on treating patients with a range of gastrointestinal and rare cancers, collaborating with others to develop novel therapies and to strengthen early clinical research. His extensive experience in drug development includes over 200 clinical trials focusing on novel agents for translational and early clinical research. Previously at the Huntsman Cancer Institute he was the Deputy Director, the Co-Leader of the Experimental Therapeutics Program and the Director of the Center for Investigational Therapeutics.
Skip to content